ArticlePharmacoepidemiology and drug safety2025
Impact and Effectiveness of COVID-19 mRNA Vaccination Against COVID-19 Hospitalisation in Paediatrics: A Cohort Study Using Two Linked Data Sources in Spain.
Article in Pharmacoepidemiology and drug safety, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Impact and Effectiveness of COVID-19 mRNA Vaccination Against COVID-19 Hospitalisation in Paediatrics: A Cohort Study Using Two Linked Data Sources in Spain.Pharmacoepidemiology and drug safety · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
purposeDespite Spain's > 2 million COVID-19 paediatric cases before 2024, few required hospitalisations (8900). We aimed to estimate the effectiveness of two-dose COVID-19 vaccinations against hospitalisation 'with' and 'for' COVID-19 in paediatrics.
methodsAll individuals aged 5-14 years between January 2021 and February 2022 in two databases in Spain (SIDIAP and BIFAP) vaccinated against COVID-19 (two doses) were matched 1:1 to unvaccinated controls with the same age, sex, region and comorbidities on the dates of vaccination. Individuals with previous SARS-CoV-2 infections were excluded. COVID-19 was identified as the main reason (hospitalisation 'for' COVID-19; SIDIAP) or as one of the reasons (hospitalisation 'with' COVID-19; BIFAP) for hospitalisation with a positive SARS-CoV-2 test ±30 days. Incidence rate differences and vaccine effectiveness (VE; 95% CI; controlled by inverse probability weights) against hospitalisations 'for' and 'with' COVID-19 were calculated.
resultsThe cohorts included 75 361 (SIDIAP) and 178 589 (BIFAP) pairs. Among vaccinated individuals (99.99% with mRNA vaccines) and controls, < 5 and 15 hospitalisations 'for' COVID-19 were identified (SIDIAP), whereas 21 and 32 hospitalisations 'with' COVID-19 (BIFAP), all aged 12-14 years old. Vaccination prevented 2.5 hospitalisations 'for' and 0.5 'with' COVID-19 during the Delta period, and 0.8 hospitalisations 'with' COVID-19 during Omicron predominance per 10
conclusionsGiven the low incidence of hospitalised COVID-19, two-dose series mRNA vaccination showed moderate-high effectiveness with few averted cases. Including hospitalisation 'with' COVID-19 underestimated the effectiveness. If paediatric severe COVID-19 remains rare, larger databases are required to understand precisely the effectiveness and impact of new vaccines.
trial registrationEU PAS Register number: EUPAS47725.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.